michael chin | $1 million boost to pediatric cancer research
TRANSCRIPT
$1 MILLION BOOST TO PEDIATRICCANCER RESEARCH
Everything You Need To Know About the New
B Y M I C H A E L C H I N
A NEW GROUP O FL EADERS
Pediatr ic cancer research just scored a big win . In July , four
young pediatr ic cancer researchers were awarded $1 mill ion in
fel lowship money to pursue innovative treatments for an area
of cancer that 's largely underfunded .
DE F I N I NG TH E NE EDSince cancer happens less much of the t ime in youngsters and
teens than in grown -ups , pediatr ic cancer research does not get
noteworthy f inancing f rom either the National Cancer Inst itute
or the biopharmaceutical business .
Of course , this then means that are fewer advances and fewer
researchers in this f ie ld .
The Damon Runyon Cancer Research Foundation and Sohn
Conference Foundations combined efforts to award four
outstanding young scientists as recipients of the prest igious
Damon Runyon -Sohn Pediatr ic Cancer Research Fel lowship ,
The fel lows represent some of the best and brightest minds in
the medical f ie ld who wil l take an intrepid approach to tackl ing
cancers in chi ldren and young adults .
MEET TH E F E L L OWSChall ice L . Bonifant , MD , PhD
1
2
3
3
4
Dr . Bonifant wil l study how best to direct the immune system to
combat acute myeloid leukemia (AML ) , a blood cancer of both chi ldren
and adult . The goal : Develop new strategies to treat AML .
Michael A . Koldobskiy , MD , PhDDr . Koldobskiy wil l study the ways that cancer cel ls rely on chemical
marks that modify the expression of genes . The goal : Identi fy new
targets for treatment of pediatr ic acute lymphoblast ic leukemia ,
Tamara P . Miller , MDDr . Mil ler wil l study the toxicit ies of cancer treatment and improving
how the s ide effects of leukemia treatment are reported .The goal :
Define the true rates of toxicit ies of leukemia therapy
Cara A . Rabik , MD , PhDDr . Rabik wil l study how mutations in the WT1 gene result in
methylat ion changes in acute myeloid leukemia . The goal : Evaluate i f
certain drugs can eff ic iently treat this part icular mutation .
With the hard work and insight of thesefour doctors--and many others--we'll
continue making strides in thisparticularly underserved area of
research.